Cannabinoid

Cannabinoid research
#Assays #BMG Labtech #Cannabinoid #Drug discovery

The study of cannabinoid-based drugs: developments and opportunities

This paid-for advertorial by BMG Labtech appeared in DDW Volume 27 – Issue 1, Winter 2025/2026.   Scientists are exploring new strategies to advance drug discovery and development related to cannabinoid research due to significant unmet needs in different therapeutic areas. Microplate-based interaction assays show promise for the study of a wide range of cannabinoid signalling events. Developments in cannabinoid research… Read More

#Exclusive Content

Cannabis research
#Cannabinoid #Medicinal cannabis #Plant-based #UK

Cannabinoid pharmaceutical development: A golden opportunity

Professor Trevor Jones, Co-Chair of the Cannabinoid Research and Development Group (CRDG), discusses how the UK could become a leader in cannabinoid research. The UK is a global leader in biotechnology and one of the top countries for cannabinoid R&D – only Canada and the US publish more cannabinoid research. Read More

#Exclusive Content #Opinion

Science, Safety, Research, Technology and Cannabis
#Addiction #Aelis Farma #Cannabinoid #Clinical trials #Medicinal cannabis

Is this drug the answer to cannabis addiction?  

Brain disease specialist Aelis Farma has announced results from the clinical Phase IIB trial study of AEF0117, evaluating its efficacy and safety in treatment-seeking participants with moderate to severe Cannabis Use Disorder (CUD) that used cannabis ≥5 days/week at baseline.    In this study population, 82% of… Read More

#News

Clinical trial
#Cannabinoid #Clinical trial design #Clinical trials #Contract Research Organisations (CROs) #Decentralised clinical trials #Medicinal cannabis #Plant-based

New podcast: How to utilise clinical trials in drug discovery

This is the latest episode of the free DDW narrated podcast, titled “How to utilise clinical trials in drug discovery” which covers three articles written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: Medicinal cannabis: Why more clinical… Read More

#News

Medicinal cannabis
#Addiction #Cannabinoid #Medicinal cannabis #Plant-based

Cutting a path through the weeds with cannabis research

Dr Currien MacDonald, Medical Chair Director at WCG, discusses the challenges and opportunities presented by cannabis research. The recent interest in cannabinoids as potential sources for medicinal use has been a long time coming. Advances in brain science and modern chemistry are supporting a new generation of investigation into cannabinoids,… Read More

#Exclusive Content

Medicinal cannabis
#Advertorial #BMG Labtech #Cannabinoid #Medicinal cannabis #Microplate readers

How microplate readers can support cannabinoid research

This paid-for advertorial by BMG Labtech appeared in DDW Volume 25 – Issue 2, Spring 2024. Cannabinoid research has gained significant attention in recent years, as scientists have been exploring the potential therapeutic benefits of these compounds. From studying their role in treating neurological disorders to pain management, this field of… Read More

#Exclusive Content

Hemp plants being used in scientific research
#Cannabinoid #Medicinal cannabis #Neuroscience #Phase I trial #Sapient Therapeutics

Positive Phase I results for solid dose prescription CBD medicine

Positive Phase I results for a new solid dose prescription cannabidiol (CBD) demonstrate the tolerability and bioavailability of the drug. Neuroscience drug discovery company Sapient Therapeutics successfully completed Part B of the Phase I trial comparing its CBD therapy SAP021 with Epidiolex. The trial… Read More

#News

Science, Safety, Research, Technology and Cannabis
#Cannabinoid #Medicinal cannabis #Plant-based #Regulatory

Where is the promise for plant-based medicines? Part 1: Cannabis  

In the first part of this series of articles focused on plant-based medicines, DDW’s Megan Thomas evaluates the use of medical cannabis in drug discovery. What is the regulatory landscape of medical cannabis?  Medical cannabis is often a first-thought when regarding plant-based medicines, but there remains… Read More

#Exclusive Content #Regulatory #Trends & Analysis

Raphael Mechoulam
#Cannabinoid #Medicinal cannabis #Obituary #Plant-based #THC

The ‘father of cannabis research’ dies aged 92

World pioneer in cannabis research, Professor Raphael Mechoulam, has died in Israel at the age of 92. A professor in the Hebrew University School of Pharmacy, Mechoulam began his cannabinoid experiments in the 1960s in Israel. His research team was the first to isolate… Read More

#News

#Cannabinoid #Oncology

Cannabotech targets US market with partnership 

Biomedical startup Cannabotech has partnered with the Californian corporation go NXT LVL in a move which will enable it to manufacture cannabidiol products in California.  Specifically, the agreement will allow Cannabotech’s integrative oncology products to be developed and manufactured at Go NXT LVL’s facilities… Read More

#News

#Biomedical research #Cancer #Cannabinoid #Oncology #Plant-based

Can cannabis and mushroom-based products eliminate colon cancer cells?

Cannabotech, a biomedical company developing oncological products based on cannabis and mushroom extracts, reports cell model study results showing that its ‘integrative-colon’ products killed over 90% of colon cancer cells. These products are based on a combination of several cannabinoids from the cannabis plant and various mushroom extracts. The study… Read More

#Cancer Research #Editor's Choice #News #Trending News

#Biologics #Cannabinoid #Cell programming

Partnership achieves equity milestone to produce cannabinoids 

Cronos Group and Ginkgo Bioworks have achieved the first target productivity milestone in their partnership to produce eight cultured cannabinoids.   Using Ginkgo’s platform for organism design and development, Cronos Group has successfully achieved the productivity target for cannabigerolic acid (CBGA), which will support Cronos Group’s planned CBG product launch this fall. … Read More

#News

#Cannabinoid #Medicinal cannabis #Pharmaceuticals

GW Pharmaceuticals’ cannabidiol treatment for seizures approved

The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved a new indication for GW Pharmaceutical’s cannabidiol as an adjunctive treatment of seizures associated with tuberous sclerosis complex (TSC), for patients two years of age and older. GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an… Read More

#News

#Cannabinoid #Drug design #Drug discovery #Medicinal cannabis #Pharma

Cultivating cannabis for pharmaceuticals: an inside view

Botanical Holdings was founded in early 2020 with a focus on investing within the legal cannabis sector. There is now a substantial body of evidence to support the effectiveness of cannabis-based medicines in treating a range of conditions from epilepsy to chronic pain. More recently, attention has also turned to… Read More

#Business & Investment #Editor's Choice #News #Opinion